Proliferative activity in primary breast carcinomas is a salient prognostic factor-Reference-Cited by-同舟云学术

Proliferative activity in primary breast carcinomas is a salient prognostic factor

Published:2004 Issue:3 Volume:100 Page:455-464
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Michels Jean-Jacques,Marnay Jacques,Delozier Thierry,Denoux Yves,Chasle Jacques

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.11916/fullpdf

Reference54 articles.

1. Prognostic Factors in Breast Cancer

2. Systemic Therapy in Resectable Breast Cancer

3. Systemic Adjuvant Therapy for Node-Negative Breast Cancer: Proven or Premature?

4. Malignant tumors of the breast. In: editors. Cancer: principles and practice of oncology. ( 5th edition) Philadelphia: Lippincott-Raven, 1997: 1591-1592.

5. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic relevance of the mitotic activity index in axillary lymph node-negative breast cancer;Breast Cancer Research and Treatment;2014-12-21

2. The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy;Cancer Letters;2014-12

3. A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial;Annals of Oncology;2013-09

4. DNA Ploidy is an Independent Predictor of Survival in Breast Invasive Ductal Carcinoma: A Long-term Multivariate Analysis of 393 Patients;Annals of Surgical Oncology;2012-12-20

5. Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers;Annals of Oncology;2012-04